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Abstract: Although numerous previous studies have explored various
biomarkers for their ability to predict mortality in end-stage renal
disease (ESRD) patients, these studies have been limited by retro-
spective analyses, mostly prevalent dialysis patients, and the measure-
ment of only 1 or 2 biomarkers. This prospective study was aimed to
evaluate the association between 3 biomarkers and mortality in incident
335 ESRD patients starting continuous ambulatory peritoneal dialysis
(CAPD) in Korea. According to the baseline NT-proBNP, cTnT, and
hsCRP levels, the patients were stratified into tertiles, and cardiovas-
cular (CV) and all-cause mortalities were compared. Additionally, time-
dependent ROC curves were constructed, and the net reclassification
index (NRI) and integrated discrimination improvement (IDI) of the
models with various biomarkers were calculated. We found the upper
tertile of NT-proBNP was significantly associated with increased risk of
both CV and all-cause mortalities. However, the upper tertile of hsCRP
was significantly related only to the high risk of all-cause mortality even
after adjustment for age, sex, and white blood cell counts. Moreover,MD, PhD, Nam-H D,
ang, MD, PhD
prognostic factor for CV mortality than cTnT and hsCRP, whereas
hsCRP is amore significant predictor than NT-proBNP and cTnT for all-
cause mortality in incident peritoneal dialysis patients.
(Medicine 94(44):e1636)
Abbreviations: CAD = coronary arterial disease, CAPD =
continuous ambulatory peritoneal dialysis, cTnT = cardiac
troponin T, CVD = cardiovascular disease, ECG = electro-
cardiogram, ESRD = end-stage renal disease, HD = hemo-
dialysis, hsCRP = high-sensitivity C-reactive protein, LAD = left
atrial dimension, LVEF = left ventricular ejection fraction, LVH =
left ventricular hypertrophy, LVMI = left ventricular mass index,
NT-proBNP = N-terminal pro B-type natriuretic peptide, PAD =
peripheral arterial disease.
INTRODUCTION
C ardiovascular disease (CVD) is a prevalent disease, and isthe most common cause of death in patients with end-stage
renal disease (ESRD).1–4 Even though traditional risk factors
for CVD, such as advanced age, diabetes mellitus (DM),
hypertension, volume overload, and dyslipidemia, are fre-
quently accompanied by ESRD,5,6 it is difficult to conclude
that the high prevalence of CVD is entirely due to these
traditional risk factors. Therefore, numerous studies have inves-
tigated alternative ways to stratify CVD risk in this population.7
Recently, several biochemical markers, such as B-type natriure-
tic peptide (BNP), N-terminal proBNP (NT-proBNP), cardiac
troponin T (cTnT), and high-sensitivity C-reactive protein
(hsCRP) have been demonstrated to provide additional help
in CVD risk stratification7-10.
Plasma BNP and NT-proBNP concentrations are increased
in patients with abnormal left ventricular (LV) structure and
function,11,12 whereas cTnT, a component of the contractile
apparatus of the heart muscle, is increased in myocardial
infarction patients.7,13 Previous studies have shown that
BNP, NT-proBNP, and cTnT are significant predictors of
CV and all-cause mortalities not only in the general population,
but also in patients with specific diseases, including
ESRD.7,9,10,14,15 Meanwhile, uremia-related nontraditional risk
factors, such as inflammation, play a role in the pathogenesis
and are associated with the clinical outcomes of CVD in ESRD
patients on dialysis.16,17 Supporting this notion, a number ofd that there is a significant correlation
hsCRP, a marker of inflammation, and
ents6,10,18,19.
www.md-journal.com | 1
As aforementioned, several biomarkers have been demon-
strated to be significantly associated with CV and all-cause
mortalities in ESRD patients, but the majority of the previous
studies were retrospective, included small numbers of patients
and mostly prevalent dialysis patients, and measured only 1 or 2
biomarkers.8–10,15 In this study, therefore, we compared the
prognostic power of NT-proBNP, cTnT, and hsCRP for CV and
all-cause mortalities in the Korean incident ESRD patients who
commenced with the continuous ambulatory peritoneal dialysis
(CAPD). In addition, the association between these 3 bio-
markers and echocardiographic parameters was assessed.
PATIENTS AND METHODS
Patients
All ESRD patients who started CAPD between August 1,
2009 and December 31, 2012 at the 36 centers of the Clinical
Research Center for ESRD in Korea were initially recruited for
this prospective observational multicenter study. This study was
part of the nationwide multicenter joint network prospective
cohort study on ESRD patients in Korea, designed to improve
survival rates and quality of life, and to draw up effective
treatment guidelines (clinicaltrial.gov NCT00931970). Among
these patients, we excluded patients who were younger than 18
years, had a history of hemodialysis (HD) or kidney transplan-
tation before CAPD, had an underlying active malignancy, or
were expected to survive<3 months. Patients who died within 3
months of the initiation of CAPD or failed to maintain CAPD
for >3 months were also excluded. Ultimately, a total of 335
incident CAPD patients were included in the final analysis.
The study protocol was approved by the Institutional Review
Board of each participating center and all patients provided their
written informed consent to participate in the study.
Data Collection
Patients’demographic and clinical data, such as age and sex,
body mass index (BMI), comorbid conditions, and medications,
were collected at the time of study enrollment. Cardiovascular
disease was defined when the patients had a history of coronary,
cerebrovascular, and/or peripheral vascular disease. We specified
coronary artery disease (CAD) when the patients had a history of
angina, myocardial infarction, coronary angioplasty, or coronary
artery bypass grafts, cerebrovascular disease when they have
experienced transient ischemic attack, stroke, or carotid endar-
terectomy, and peripheral arterial disease (PAD) when there was a
history of claudication, any peripheral revascularization pro-
cedure, or ischemic limb loss and/or ulceration. The following
laboratory data were measured from fasting blood samples, which
were drawn at 2 hours after the first peritoneal dialysis (PD)
exchange with 1.5% dextrose dialysate, at the time of study
enrollment and every 3 months thereafter: hemoglobin (Hb),
white blood cell (WBC) count, calcium, phosphorus, intact
parathyroid hormone (iPTH), albumin, total cholesterol, trigly-
ceride, sodium, potassium, bicarbonate, NT-proBNP, cTnT, and
hsCRP. The preceding overnight dwell was regulated to 1.5%
dextrose dialysate to make the glucose load same. Body weight
was checked in the morning, on the same day as when the first
dialysate was drained out.
The Elecsys proBNP electrochemiluminescence immu-
noassay (Roche Diagnostics, Indianapolis, IN) and a third-
Oh et algeneration electrochemiluminescence immunoassay (Elecsys
Troponin T STAT Immunoassay, Roche Diagnostics) were used
to determine NT-proBNP and cTnT concentrations, respectively.
2 | www.md-journal.comMoreover, a latex-enhanced immunonephelometric method using
a BNII analyzer (Dade Behring, Newark, DE) was applied for the
measurement of hsCRP levels. The modified peritoneal equili-
bration test was performed with 4.25% glucose dialysis solution
as described previously.20 Furthermore, peritoneal transport
characteristics were classified as high, high average, low average,
and low based on the results of dialysate-to-plasma creatinine (D/
P Cr) and glucose (D/D0 glucose) concentration ratios at 4 hours
of dwell.
Electrocardiogram and Echocardiography
LV hypertrophy (LVH) was determined by the results of
baseline electrocardiogram (ECG) and echocardiography. By
ECG, LV hypertrophy was defined if the products of the Cornell
voltage combination (with 6 mm added in women) multiplied
by QRS duration was 2440 mm/msec.21 Echocardiography
was performed with an empty abdomen close to the time of
discharge, when the patients were considered to be clinically
stable and in a euvolemic state. Two-dimensional echocardio-
graphy was performed with patients lying in the left decubitus
position, based on the imaging protocol recommended by the
American Society of Echocardiography.22 The LV ejection
fraction (LVEF), which was assessed with a modified biplane
Simpson method from the apical 2-chamber and 4-chamber
views, was regarded as an index of LV systolic function. In
addition, the method of Devereux23 was used to determine LV
mass, and LV mass index (LVMI) was calculated by dividing the
LV mass by the body surface area (g/m2). According to the
leading-edge-to-leading-edge convention, left atrial dimension
(LAD) was measured at the aortic valve level at the ventricular
end-systolic point. We also evaluated multiple reproducibility,
intrareader reliability, inter-reader reliability, and reader drift
analyses at Kyungpook National University (Daegu, Korea), a
core echocardiography laboratory using a random sample of 3%
of the entire cohort every year. The intra-class correlation
coefficients for the echocardiographic measures were revealed
to be 0.822, 0.801, and 0.796 for LVEF, LVMI, and LAD,
respectively. Systolic and diastolic blood pressures (BPs) were
measured at the time of echocardiography after resting for
15 min.
Assessment of Residual Renal Function and
Dialysis Indices
Residual renal function (RRF) and dialysis adequacy were
measured at 1 month after PD initiation. RRF was calculated as
an average of the 24-hour urine urea and creatinine clearances.24
To assess the dialysis adequacy, weekly Kt/V urea was calcu-
lated as the ratio of the 24-hour urinary and drained dialysate
urea clearance to total body water, which was derived using the
Watson formula.25–27 Peritoneal transport characteristics were
determined using the equilibration ratios between dialysate and
plasma creatinine.
Outcome Measures
All patients were followed up prospectively after all the
baseline assessments. All mortality events were retrieved from
the database and carefully reviewed. CV mortality was defined
as death from myocardial infarction or ischemia, congestive
heart failure, pulmonary edema, and cerebrovascular disorder,
or peripheral vascular disease. The primary and secondary
Medicine  Volume 94, Number 44, November 2015endpoints were CV and all-cause mortalities, respectively.
Loss to follow-up, renal transplantation, transfer to HD, and
recovery of renal function after the first 3 months of PD
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.
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4 | www.md-journal.comcommencement were censored at the end of the PD treatment.
When a patient died within 3 months after being transferred to
HD, the death was regarded as a mortality event.
Statistical Analysis
Statistical analyses were performed using the SPSS for
Windows, version 18.0 (SPSS Inc., Chicago, IL) and SAS 9.2
version (SAS Institute Inc, Cary, NC). Continuous variables
were expressed as mean standard deviation and categorical
variables as a number (percentage). According to the baseline
NT-proBNP, cTnT, and hsCRP levels, the patients were strati-
fied into tertiles (lower, middle, and upper groups), and the
baseline characteristics were compared among the 3 groups
using ANOVA for continuous variables and the x2 test for
categorical variables. The relationships among NT-proBNP,
cTnT, hsCRP, WBC, LVEF, LVMI, and LAD were determined
by the Pearson correlation analysis. Cumulative survival curves
were created by the Kaplan-Meier method, and between-group
survival was compared by a log-rank test. To assess the
additional effect of each biomarker on the null model, moreover,
multivariate regression analyses with a null model (including
age and sex, and WBC count) and each biomarker were
performed. For the null model, we applied the backward method
(specifies the significance level for entering effects and remov-
ing effects¼ 0.05) to the candidate list of traditional risk factors;
age and sex, BMI, DM, hypertension, Charlson Comorbidity
Index, mean arterial pressure (MAP), 24-hour urine output, Hb,
WBC count, and serum albumin and total cholesterol levels, and
found that the WBC count was only a significant risk factor for
CV and/or all-cause mortality. Therefore, age and sex, and the
WBC count were chosen for the variables of the null model.
Furthermore, a time-dependent receiver-operating character-
istic (ROC) curve was created to determine which biomarkers
added up the higher predictive value.28–30 We compared the
global concordance probability (integrated area under the curve
[iAUC]) between the null model and each biomarker by using
the R Statistical package ver. 3.0.1 (www.R-project.org). The
net reclassification index (NRI) and the integrated discrimi-
nation improvement (IDI) were also estimated to assess the
power of the models with biomarkers to correctly reclassify
patients compared with the model without biomarkers (model
including the null model and each biomarker). Since the
definition of risk strata for NRI was needed, 3 risk strata was
defined for CV and all-cause mortalities based on 3 point:
<33.3%, 33.3% to 66.6%, and >66.6%. In the NRI, only the
changes in predicted probabilities, which indicate a change
from one to another category, were considered. Therefore,
the NRI could explain the global net improvement in reclassi-
fication with the new model. For the IDI, in contrast, we
considered the change in the predicted probabilities as a con-
tinuous variable because the IDI did not need a prior definition
of risk strata.31 P values <0.05 were considered statistically
significant.
RESULTS
Patient Characteristics
Baseline patient characteristics are shown in Table 1.
When baseline patient characteristics were compared among
the 3 groups based on the tertile values of NT-proBNP (1255.8
and 8720.5 pg/mL), cTnT (0.027 and 0.06 ng/mL), and hsCRP
Medicine  Volume 94, Number 44, November 2015(0.07 and 0.65mg/dL), the mean values of LVMI and LAD, and
the proportions of patients with DM and LVH on ECG,
increased significantly across the three tertiles of NT-proBNP
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.
TABLE 2. Comparisons of Clinical Outcomes Between Each Group Stratified Based on the Tertile Value of Cardiac Biomarkers
Variables
Total
(N¼ 335)
NT-proBNP, pg/mLz cTnT, ng/mL§ hsCRP, mg/dL
Lower
(N¼ 111)
Middle
(N¼ 111)
Upper
(N¼ 113)
Lower
(N¼ 114)
Middle
(N¼ 108)
Upper
(N¼ 113)
Lower
(N¼ 113)
Middle
(N¼ 109)
Upper
(N¼ 113)
Follow-up duration, mo 21.5 8.5 22.0 8.7 22.0 8.7 21.9 8.6 20.4 6.9 21.3 8.1 22.2 9.4 22.2 7.3 21.8 8.5 21.9 8.1
All-cause mortality,
n (%)
39 (11.6%) 4 (3.6%) 6 (5.4%) 29 (25.7%)y 3 (2.6%) 16 (14.8%) 20 (17.7%) 3 (2.7%) 9 (8.3%) 27 (23.9%)

Cardiovascular
mortality, n (%)
22 (6.6%) 2 (1.8%) 4 (3.6%) 16 (14.2%)

3 (2.6%) 7 (6.5%) 12 (10.6%)

3 (2.7%) 7 (6.4%) 12 (10.6%)
Data are presented as n (%) or meanSD. cTnT¼ cardiac troponin T, hsCRP¼ high-sensitivity C-reactive protein, NT-proBNP¼N-terminal proB-type natriuretic peptide.
Comparison among the 3 tertiles and the P< 0.05.y
Comparison among the 3 tertiles and the P<0.01.
z
The tertile of NT-proBNP was 1255.8 and 8720.5 pg/mL.
Medicine  Volume 94, Number 44, November 2015 Cardiovascular Biomarkers, Mortality Risk in Incident PDand cTnT. In contrast, serum albumin concentrations and LVEF
decreased significantly across the 3 tertiles of NT-proBNP and
cTnT. In the hsCRP group, however, significant increases in age
and WBC counts and significant decreases in Hb and serum
albumin levels were observed across the 3 tertiles of hsCRP.
However, there were no significant differences in Charlson
Comorbidity Index, MAP, iPTH concentrations, PD-related
variables, and the proportion of patients treated with vitamin
D supplements or analogues among the tertiles of NT-proBNP,
cTnT, and hsCRP (Table 1).
Next, we compared CV and all-cause mortalities among
each tertile group. There were significant increases in CV and
all-cause mortalities across the 3 tertiles of NT-proBNP (CV
mortality: 14.2% vs 3.6% vs 1.8%, P< 0.05; all-cause
mortality: 25.7% vs 5.4% vs 3.6%, P< 0.01). On the contrary,
only CV mortality and only all-cause mortality were signifi-
cantly different among the tertile groups of cTnT (10.6%, 6.5%,
and 2.6%, P< 0.05) and hsCRP (23.9%, 8.3%, and 2.7%,
P< 0.05) (Table 2), respectively.
Correlations Among Biomarkers and Other
Parameters
Baseline NT-proBNP concentrations had positive corre-
§
The tertile of cTnT was 0.027 and 0.06 ng/mL.

The tertile of hsCRP was 0.07 and 0.65mg/dL.lations with cTnT levels (r¼ 0.236, P¼ 0.004), WBC counts
(r¼ 0.156, P¼ 0.047), LVMI (r¼ 0.233, P¼ 0.004), and LAD
(r¼ 0.304,P< 0.001).An inverse relationshipwas demonstrated
TABLE 3. Pearson Correlations Among Biomarkers and Other Pa
NT-proBNP, pg/mL cTnT, ng/mL hsCRP, mg/dL
NT-proBNP, pg/mL 1 0.236, P¼ 0.004 0.114, P¼ 0.079
cTnT, ng/mL 1 0.234, P¼ 0.002
hsCRP, mg/dL 1
WBC, cells/mm3
LVEF (%)
LVMI, g/m2
LAD, cm
cTnT¼ cardiac troponin T, hsCRP¼high-sensitivity C-reactive protein, LAD¼ left at
mass index, NT-proBNP¼N-terminal proB-type natriuretic peptide, WBC¼white blo
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.between NT-proBNP levels and LVEF (r¼0.502, P< 0.001).
In addition, there were positive associations of cTnT values with
hsCRP concentrations (r¼ 0.234, P¼ 0.002), WBC counts
(r¼ 0.127, P¼ 0.029), LVMI (r¼ 0.158, P¼ 0.044), and LAD
(r¼ 0.194, P¼ 0.015). A negative correlation was observed
between cTnT concentrations and LVEF (r¼0.335,
P< 0.001). There was also a positive association of baseline
hsCRP levels withWBC counts (r¼ 0.201, P¼ 0.013) (Table 3).
Additionally, we performed Pearson correlation analysis includ-
ing NT-proBNP, MAP, and daily urine volume and PD ultra-
filtration volume. NT-proBNP levels were not significantly
associated with MAP and daily PD ultrafiltration volume. How-
ever, there was a significantly negative association between NT-
proBNP concentrations and daily urinary volume (r¼0.137,
P¼ 0.002) in spite of comparable amount of daily urinary andPD
ultrafiltration volumes among the tertile of NT-proBNP. Further-
more, serum albumin levels were significantly and inversely
correlated with all these biomarkers (r¼0.172, P¼ 0.031
for NT-proBNP; r¼0.190, P¼ 0.027 for cTnT; and
r¼0.079, P¼ 0.042 for hsCRP), whereas there were no sig-
nificant associations of the amount of urinary protein excretion
with all these biomarkers (r¼ 0.132, P¼ 0.211 for NT-proBNP;
r¼ 0.090, P¼ 0.177 for cTnT; r¼ 0.079, P¼ 0.453 for hsCRP).
Meanwhile, there were no significant differences in NT-proBNP,
CRP levels, and iPTH concentrations between patients with and
without vitamin D supplements or analogues treatment.
rameters
WBC, cells/mm3 LVEF (%) LVMI (g/m2) LAD, cm
0.156, P¼ 0.047 –0.502, P< 0.001 0.233, P¼ 0.004 0.304, P< 0.001
0.127, P¼ 0.029 –0.335, P< 0.001 0.158, P¼ 0.044 0.194, P¼ 0.015
0.201, P¼ 0.013 0.062, P¼ 0.187 –0.067, P¼ 0.174 0.100, P¼ 0.080
1 –0.074, P¼ 0.276 0.113, P¼ 0.104 0.140, P¼ 0.043
1 –0.210, P¼ 0.001 –0.332, P< 0.001
1 0.163, P¼ 0.011
1
rial dimension, LVEF¼ left ventricular ejection fraction, LVMI¼ left ventricular
od cell counts.
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FIGURE 1. Kaplan-Meier survival curves for cardiovascular and all-cause mortality based on the median baseline values of NT-proBNP (A/
ntl
dif
igni
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D), cTnT (B/E), and hsCRP (C/F). The CV survival rates were significa
the corresponding ‘‘low’’ groups, whereas there was no significant
groups (A, B, and C). However, the all-cause mortality rates were s
troponin T, CV¼ cardiovascular, hsCRP¼high-sensitivity C-reactivConcentrations
During amean follow-up duration of 21.5 8.5 months, 39
patients (11.6%) died. Among them, 22 patients (56.4%) died
from CV causes, and 11 patients (28.2%) due to infection.
FIGURE 2. Time-dependent ROC curve analyses for cardiovascular (A) a
(95% CI, 0.545–0.694) for null model, 0.725 (95% CI, 0.602–0.771)
null model plus cTnT, and 0.663 (95% CI, 0.592–0.703) for null mode
0.041–0.178) for NT-proBNP, 0.064 (95% CI, 0.005–0.156) for cTnT,
these 3 biomarkers were additional significant prognostic factors for CV
predictive factor for CVmortality among them.On the contrary, iAUC v
null model, 0.669 (95% CI, 0.571–0.771) for null model plus NT-proB
and the ESD in iAUC values for all-cause mortality were 0.048 (95% CI
for hsCRP. However, iAUC for all-cause mortality was 0.640 (95% CI, 0
cTnT for all-cause mortality was only 0.019 (95% CI, 0.005 to 0.
cardiovascular, ESD¼ estimated difference, hsCRP¼high-sensitivity
proBNP¼N-terminal proB-type natriuretic peptide, ROC¼ receiver-o
6 | www.md-journal.comFurthermore, 26 patients (7.8%) were transferred to HD, and 21
patients (6.3%) received a kidney transplant. As shown in
y lower in the ‘‘high’’ NT-proBNP and cTnT groups compared with
ference in CV survival rates between the ‘‘high’’ and ‘‘low’’ hsCRP
ficantly higher in all 3 ‘‘high’’ groups (D, E, and F). cTnT¼cardiac
rotein, NT-proBNP¼N-terminal proB-type natriuretic peptide.Figure 1, CV mortality rates were significantly higher in the
‘‘upper’’ tertile of NT-proBNP compared with the ‘‘middle’’
and ‘‘lower’’ tertiles of NT-proBNP (P¼ 0.030), but there were
nd all-causemortality (B). iAUC values for CVmortality were 0.620
for null model with NT-proBNP, 0.685 (95% CI, 0.650–0.792) for
l with hsCRP. The estimated difference in iAUC was 0.105 (95% CI,
and 0.043 (95% CI, 0.001–0.152) for hsCRP, indicating that all of
mortality, but NT-proBNPwas revealed to be the significantlymost
alues for all-causemortality were 0.621 (95%CI, 0.534–0.722) for
NP, and 0.675 (95% CI, 0.564–0.786) for null model with hsCRP,
, 0.001–0.158) for NT-proBNP and 0.055 (95% CI, 0.001–0.163)
.551–0.739) for the null model plus cTnT, and the ESD in iAUC of
093). CI¼ confidence interval, cTnT¼cardiac troponin T, CV¼
C-reactive protein, iAUC¼ integrated area under curve, NT-
perating curve.
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no significant differences in CV mortality among the tertiles of
cTnT (P¼ 0.078) and hsCRP (P¼ 0.486). Meanwhile, all-cause
mortality rates increased significantly across the 3 tertiles of
NT-proBNP and hsCRP groups (NT-proBNP group, P¼ 0.019;
hsCRP group; P¼ 0.014), but not among the cTnT tertiles
(P¼ 0.232).
Time-dependent ROC curves over the entire follow-up
period are presented in Figure 2. iAUC values for CV mortality
were 0.620 (95% CI, 0.545–0.694) for the null model (includ-
ing age, sex, and WBC counts), 0.725 (95% CI, 0.602–0.771)
for the null model with NT-proBNP, 0.685 (95% CI, 0.650–
0.792) for the null model plus cTnT, and 0.663 (95%CI, 0.592–
0.703) for the null model with hsCRP. The estimated differ-
ences (ESDs) in iAUC were 0.105 (95% CI, 0.041–0.178) for
NT-proBNP, 0.064 (95% CI, 0.005–0.156) for cTnT, and 0.043
(95% CI, 0.001–0.152) for hsCRP, indicating that all of these 3
biomarkers provided additional significant prognostic values
for CV mortality. However, among them, NT-proBNP was the
most significant additional predictive factor for CV mortality.
In contrast, iAUC values for all-cause mortality were 0.621
(95% CI, 0.534–0.722) for the null model, 0.669 (95% CI,
0.571–0.771) for the null model plus NT-proBNP, and 0.675
(95% CI, 0.564–0.786) for the null model with hsCRP. The
ESDs in iAUC values for all-cause mortality were 0.048 (95%
CI, 0.001–0.158) for NT-proBNP, and 0.055 (95% CI, 0.001–
Medicine  Volume 94, Number 44, November 20150.163) for hsCRP, suggesting that both NT-proBNP and hsCRP
were additional significant prognostic factors for all-cause
mortality. Furthermore, hsCRP was considered to be more
TABLE 4. Univariate Cox Proportional Regression Analysis for Ca
Variables
Cardiovascular Mortality
HR (95% CI)
Age, y 0.995 (0.965-1.026)
Male (vs female) 0.680 (0.318–1.452)
BMI, kg/m2 1.067 (0.955–1.193)
DM (vs non-DM) 1.597 (0.730–3.495)
CCI 1.083 (0.933–1.256)
MAP, mmHg 0.984 (0.958–1.011)
Urine output, mL/day 1.000 (0.999–1.000)
Hb, g/dL 0.957 (0.750–1.221)
WBC, cells/mm3 1.118 (0.997–1.254)
Serum albumin, g/dL 0.724 (0.415–1.265)
Total cholesterol, mg/dL 0.992 (0.982–1.001)
Bicarbonate, mEq/L 0.968 (0.905–1.036)
LVH on ECG 2.180 (0.640–7.425)
LVEF (%) 0.998 (0.960–1.038)
LVMI, g/m2 1.003 (0.996–1.009)
LAD, cm 0.888 (0.445–1.769)
NT-proBNP

Tertile 1 Ref
Tertile 2 1.974 (0.493–7.897)
Tertile 3 4.975 (1.417–17.47)
cTnTy
Tertile 1 Ref
Tertile 2 1.384 (0.339–5.645)
Tertile 3 3.794 (1.066–13.51)
hsCRPz
Tertile 1 Ref
Tertile 2 2.752 (0.729–10.40)
Tertile 3 4.910 (0.916–17.02)
BMI¼ body mass index, CCI¼Charlson Comorbidity Index, CI¼ confidence interval, cT
hsCRP¼ high-sensitivity C-reactive protein, LAD¼ left atrial dimension, LVEF¼ left ventric
LVMI¼ left ventricular mass index, MAP¼mean arterial pressure, NT-proBNP¼N-termin
The tertile of NT-proBNP was 1255.8 and 8720.5 pg/mL.y
The tertile of cTnT was 0.027 and 0.06 ng/mL.
z
The tertile of hsCRP was 0.07 and 0.65mg/dL.
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.significantly predictive for all-cause mortality than NT-
proBNP. However, iAUC for all-cause mortality was 0.640
(95% CI, 0.551–0.739) for the null model plus cTnT, and the
ESD in iAUC of cTnT for all-cause mortality was only 0.019
(95% CI, 0.005 to 0.093).
Biomarkers as Predictors of Mortality
The univariate Cox proportional hazard regression analysis
revealed that the ‘‘upper’’ tertiles of NT-proBNP and cTnT
were significantly associated with higher risks of both CV (NT-
proBNP: HR¼ 4.975, P¼ 0.012; cTnT: HR¼ 3.794,
P¼ 0.040) and all-cause mortalities (NT-proBNP:
HR¼ 4.199, P¼ 0.010; hsCRP: HR¼ 4.867, P¼ 0.001) com-
pared with the corresponding ‘‘lower’’ tertile groups. In
addition, the ‘‘upper’’ tertile of hsCRP was significantly associ-
ated only with the increases in the risk for all-cause mortality.
Serum albumin levels and WBC counts were also found to
significantly predict all-cause mortality but not CV mortality
(Table 4). In the multivariate Cox models, the ‘‘upper’’ tertiles
of NT-proBNP and cTnT were still significantly related to the
higher risks of CV mortality (NT-proBNP: HR¼ 4.702,
P¼ 0.018; cTnT: HR¼ 4.483, P¼ 0.021); there were signifi-
cant associations of the ‘‘upper’’ tertiles of NT-proBNP and
hsCRP with all-cause mortality (NT-proBNP: HR¼ 4.174,
P¼ 0.012; hsCRP: HR¼ 4.550, P¼ 0.003), even after adjusting
Cardiovascular Biomarkers, Mortality Risk in Incident PDfor age, sex, and WBC counts (Table 5). Moreover, we calcu-
lated the NRI and IDI to assess the ability of the models with
biomarkers to correctly reclassify patients compared with the
rdiovascular and All-Cause Mortality
All-Cause Mortality
P HR (95% CI) P
0.753 1.018 (0.993–1.044) 0.163
0.319 0.848 (0.450–1.598) 0.609
0.252 1.101 (0.782–2.367) 0.121
0.241 1.680 (0.872–3.236) 0.121
0.295 1.106 (0.984–1.244) 0.091
0.236 0.994 (0.973–1.014) 0.549
0.516 1.000 (0.999–1.000) 0.461
0.723 0.970 (0.793–1.187) 0.769
0.056 1.110 (1.008–1.222) 0.034
0.257 0.622 (0.406–0.951) 0.028
0.085 1.110 (1.008–1.222) 0.034
0.350 0.954 (0.905–1.005) 0.077
0.213 1.938 (0.917–6.972) 0.055
0.928 0.981 (0.952–1.011) 0.213
0.406 1.003 (0.997–1.008) 0.357
0.735 1.164 (0.661–2.049) 0.599
— Ref —
0.336 2.216 (0.682–7.201) 0.186
0.012 4.199 (1.408–12.52) 0.010
— Ref —
0.651 1.653 (0.567–4.818) 0.360
0.040 3.015 (0.864–8.261) 0.231
— Ref —
0.135 1.947 (0.652–5.817) 0.223
0.112 4.867 (1.852–12.79) 0.001
nT¼ cardiac troponin T, DM¼ diabetes mellitus, Hb¼ hemoglobin, HR¼ hazard ratio,
ular ejection fraction, LVH on ECG¼ left ventricular hypertrophy on electrocardiogram,
al proB-type natriuretic peptide, WBC¼white blood cell counts.
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TABLE 5(A). Multivariate Cox Proportional Regression Analysis for Cardiovascular Mortality
Null Model Model 1 Model 2 Model 3
HR (95% CI) P HR (95% CI) P HR (95% CI) P HR (95% CI) P
Age (per year) 1.001 (0.972–1.031) 0.944 1.006 (0.972–1.041) 0.750 0.982 (0.948–1.017) 0.311 0.992 (0.962–1.023) 0.618
Male (vs female) 0.690 (0.319–1.490) 0.344 0.563 (0.238–1.330) 0.190 0.422 (0.172–1.033) 0.059 0.498 (0.223–1.114) 0.090
WBC (increase by 1000 cells/mm3 1.114 (0.992–1.251) 0.068 1.009 (0.883–1.152) 0.899 1.111 (0.970–1.272) 0.129 1.036 (0.916–1.172) 0.574
NT-proBNP

Tertile1 Ref —
Tertile2 1.751 (0.431–7.109) 0.433
Tertile3 4.702 (1.299–17.03) 0.018
cTnTy
Tertile1 Ref —
Tertile2 1.463 (0.348–6.152) 0.603
Tertile3 4.483 (1.174–15.40) 0.021
hsCRPz
Tertile1 Ref —
Tertile2 3.028 (0.794–11.55) 0.105
Tertile3 5.412 (0.815–20.00) 0.091
Table 5(B). Multivariate Cox Proportional Regression Analysis for All-Cause Mortality
Null model Model 1 Model 2 Model 3
HR (95% CI) P HR (95% CI) P HR (95% CI) P HR (95% CI) P
Age (per year) 1.022 (0.997–1.048) 0.082 1.022 (0.992–1.053) 0.145 0.999 (0.971–1.029) 0.970 1.013 (0.988–1.039) 0.301
Male (vs female) 0.812 (0.427–1.545) 0.526 0.649 (0.307–1.371) 0.258 0.574 (0.28–1.176) 0.129 0.624 (0.321–1.21) 0.163
WBC (increase by 1000 cells/mm3) 1.127 (1.018–1.249) 0.022 1.028 (0.914–1.157) 0.642 1.102 (0.984–1.234) 0.094 1.048 (0.943–1.165) 0.385
NT-proBNP
Tertile1 Ref —
Tertile2 1.897 (0.573–6.277) 0.294
Tertile3 4.174 (1.368–12.74) 0.012
cTnT
Tertile1 Ref —
Tertile2 1.710 (0.576–5.074) 0.334
Tertile3 3.562 (0.865–10.03) 0.214
hsCRP
Tertile1 Ref —
Tertile2 2.064 (0.686–6.206) 0.197
Tertile3 4.550 (1.665–12.44) 0.003
CI¼ confidence interval, cTnT¼ cardiac troponin T, HR¼ hazard ratio, hsCRP¼ high-sensitivity C-reactive protein, NT-proBNP¼N-terminal proB-type natriuretic peptide,
WBC¼white blood cell counts. Null model: age, sex, and white blood cell counts; Model 1: Null modelþ tertile of NT-proBNP; Model 2: Null modelþ tertile of cTnT; Model 3: Null
modelþ tertile of hsCRP.
TABLE 6. Prognostic Power for Cardiovascular and All-Cause
Mortality for Null and Each Cardiac Biomarker Models Using
NRI and IDI
Cardiovascular Mortality All-Cause Mortality
NRI P IDI P NRI P IDI P
Model 1 0.204 0.050 0.078 0.002 0.116 0.15 0.039 0.037
Model 2 0.280 0.091 0.052 0.017 0.005 0.912 0.016 0.176
Model 3 0.010 0.317 0.010 0.239 0.249 0.015 0.052 0.008
IDI¼ integrated discrimination improvement, NRI¼ net reclassification index. Null
model: age, sex, and white blood cell counts; Model 1: Null modelþ tertile of NT-
proBNP; Model 2: Null modelþ tertile of cTnTl; Model 3: Null modelþ tertile of
hsCRP.
The data were analyzed with tertile groups of cardiac biomarkers.
Oh et al Medicine  Volume 94, Number 44, November 2015model without biomarkers (including the null model and each
biomarker). The prognostic powers of the null model and each
biomarker model are shown in Table 6. There were significant
differences in both the CV and all-cause mortalities between the
null model and the null model plus NT-proBNP, whereas cTnT
and hsCRP had significant associations with only CV and all-
cause mortalities, respectively (Table 6).
DISCUSSION
Several previous studies demonstrated that NT-proBNP,
cTnT, and hsCRP predicted CVmortality in ESRD patients, but
most of the patients included in these studies were prevalent HD
patients.9,10,15 The present study found that NT-proBNP was
independently associated with both CV and all-cause mortal-
ities in incident CAPD patients; however, cTnT was related
The tertile of NT-proBNP was 1255.8 and 8720.5 pg/mL.
yThe tertile of cTnT was 0.027 and 0.06 ng/mL.
zThe tertile of hsCRP was 0.07 and 0.65mg/dL.ly to the CV mortality, and hsCRP was related only to the all- yThe tertile of NT-proBNP was 1255.8 and 8720.5 pg/mL.
zThe tertile of cTnT was 0.027 and 0.06 ng/mL.on
cause mortality. Among these 3 biomarkers, NT-proBNP was
revealed to be the most significant predictor of CV mortality,
§The tertile of hsCRP was 0.07 and 0.65mg/dL.
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whereas hsCRP was shown to be the most significant prognostic
factor for all-cause mortality in incident CAPD patients. To our
knowledge, the present study is the first to investigate and
compare the predictive value of various biomarkers at the time
of dialysis initiation on CV and all-cause mortalities in a large,
ethnically homogeneous, incident CAPD patient cohort.
The first noticeable finding of this study was that NT-
proBNP and cTnT but not hsCRP had a significant predictive
power for CV mortality. The exact reason for the conflicting
impacts of these 3 biomarkers is not yet defined. One possible
explanation is that NT-proBNP and cTnT are more closely
linked to LVH, which is known to be significantly associated
with clinical outcomes in patients with chronic kidney dis-
ease.9,11,12,15 A number of previous studies have shown that
LVH is a powerful independent predictor of CV mortality in
ESRD patients on dialysis. Moreover, the change in LVH has
been demonstrated as a strong prognostic factor in these
patients.32,33 London et al32 found that 10% reduction in left
ventricular mass (LVM) during a mean follow-up duration of 54
months resulted in a 28% decrease in CV mortality and a 22%
decrease in all-cause mortality in ESRD patients. LVM
regression was also independently associated with better patient
survival even after adjustment for age, sex, diabetes, history of
CVD, and all the nonspecific CV risk factors.32 Although the
study used LVM and LVMI, assessed by echocardiography, as
an indicator of LVH, similar findings were observed in hyper-
tensive patients with LVH on ECG.34,35 In addition, persistent
ECG-based LVH at baseline and follow-up identified patients
with greater LVM and higher prevalence of echocardiographic
LVH, suggesting that these patients may be at a higher risk for
subsequent CV morbidity and mortality.36 In the present study,
the proportions of patients with LVH on ECG and LVMI were
significantly higher in the ‘‘upper’’ tertiles of NT-proBNP and
cTnT. Moreover, in these groups, there was a significant
decrease in LVEF and a significant increase in LAD, which
were revealed to be associated with CV mortality in dialysis
patients. Furthermore, NT-proBNP and cTnT were significantly
correlated with LVEF, LVMI, and LAD. In contrast, there were
no significant differences in the proportion of patients with
LVH on ECG, LVEF, LVMI, and LAD among the tertiles of
hsCRP. Additionally, there were no significant correlations of
hsCRP with LVEF, LVMI, and LAD. Based on these findings,
we surmise that the better predictability of NT-proBNP and
cTnT, but not hsCRP, for CV mortality was attributed to their
strong associations with LVH and systolic and diastolic dys-
function.
The cutoff value of cTnT for the ‘‘middle’’ and ‘‘upper’’
groups (0.06 ng/mL) in our study was less than the reference
cTnT concentration (0.1 ng/mL) used in most previous stu-
dies,37–39 whereas that of NT-proBNP (8720.5 pg/mL) was
comparable with the value used in other studies.9,10,15 In
addition, the proportion of CV mortality among the all-cause
mortality (22/39 [56.4%]) was somewhat lower than that of the
other studies. However, the proportion of infection-related
mortality (11/39 [28.2%]) was similar to or slightly higher than
that of the others.37,39–41 These findings may in part contribute
to a relatively lower prognostic value of cTnT for CV mortality
compared with NT-proBNP. Nevertheless, further studies are
needed to determine whether a weaker association between
cTnT and CV mortality is attributed to more meticulous care
and more intensive treatment provided for these patients.
Medicine  Volume 94, Number 44, November 2015hsCRP, a well-known inflammatory marker, has been
demonstrated to be associated with CVD because of a signifi-
cant pathogenic role of inflammation in the development and
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.progression of atherosclerosis.16,17 Moreover, a number of
previous studies have revealed that serum hsCRP levels can
predict future CV events as well as CV mortality in the general
population.16 However, the results of previous studies on the
impact of serum hsCRP concentrations on CVD or CVmortality
in ESRD patients were not consistent,10,15 which may partly be
due to the differences in the study population, the duration of
dialysis, comorbid diseases, and measurement methods. How-
ever, increased serum hsCRP levels are usually observed in
patients with diabetes, insulin resistance, and dyslipidemia, all
of which are prevalent in dialysis patients.11,42 Furthermore,
most of ESRD patients, especially CAPD patients, are
suggested to have underlying chronic low-grade inflam-
mation,43 and the concentrations of serum hsCRP levels are
also known to vary widely, both intra- and interindividu-
ally.44,45 Taken together, the prognostic value of serum hsCRP
levels for CV mortality could be lessened in our study patients.
In contrast, we found that all-cause mortality was significantly
higher in the ‘‘upper’’ tertile of hsCRP compared with the other
tertiles (23.9% vs 8.3% and 2.7%, P< 0.05). The Kaplan-Meier
plot also showed that there was a significant difference in all-
cause mortality rates among the tertiles of hsCRP (P¼ 0.014).
Moreover, the WBC count was significantly higher in the
‘‘upper’’ tertile of hsCRP and significantly correlated with
hsCRP (r¼ 0.201, P¼ 0.013). Based on these findings, it
was submitted that higher all-cause mortality in the ‘‘upper’’
hsCRP group might be attributed to deaths from infection. In
fact, infection-related mortality was significantly higher in the
‘‘upper’’ tertile of hsCRP (5.3% vs 2.8% and 1.8%, P< 0.05);
this possibly explains why hsCRP had a higher predictive value
for all-cause mortality than other biomarkers in incident CAPD
patients. Since there were a relatively small number of deaths
from infection, and hsCRP concentrations and WBC counts
were determined only once at the time of the study entry, it was
difficult to confirm the clear-cut association between hsCRP
and infection-related mortality in our study subjects.
At baseline, 143 patients were taking vitamin D supple-
ments or analogues. In the present study, additional analysis
revealed that there were no significant differences in NT-
proBNP, CRP levels, and PTH levels between patients with
and without vitamin D supplements or analogues treatment.
Even though several previous studies showed that stimulation of
vitamin D receptors reduced BNP levels,46–51 some recent
published data demonstrated that there was no significant
association between vitamin D supplements and NT-proBNP
concentrations in dialysis patients,52–54 supporting the results of
the present study.
There are several limitations to this study. First, since the
patients of the present study were all Korean ESRD patients
starting CAPD, the associations between various biomarkers
and mortality may not be applicable to other populations.
Second, we included only CAPD patients because automated
PD (APD) was not widely performed in Korea and the timing of
the change from CAPD to APD was not uniform. Third, CV and
all-cause mortality rates in this study were lower compared with
those in previous studies on Western dialysis patients.9,10,15 We
propose that a difference in ethnicities is what mainly contrib-
utes to these disparate results because the mortality rates of our
incident CAPD patients were comparable with those of the
Japanese ESRD patients on dialysis.55 Fourth, the measurement
of biomarkers and echocardiography were performed only once
Cardiovascular Biomarkers, Mortality Risk in Incident PDat the time of PD initiation. Therefore, it is difficult to clarify
why some biomarkers did not associate with CV and/or all-
cause mortality and to examine whether the changes in these
www.md-journal.com | 9
biomarkers had any impact on patient clinical outcomes. Fifth,
the patients were arbitrarily divided into the 3 groups based on
the tertile values of each biomarker. As aforementioned, the
cutoff values for each biomarker used in previous studies were
quite different.9,10,14,15 Therefore, it is necessary to define the
best cutoff levels for the various biomarkers in CAPD patients.
Sixth, unfortunately, even though an objective fluid balance
monitoring, such as inferior vena cava diameter, bioimpedance,
and continuous blood volume measurements, were not carried
out in the present study, the physicians performed routine chest
X-rays and physical examination to evaluate the volume status
of these patients, and these cardiac biomarkers were determined
at the time close to discharge. Thus, we considered the patients
to be clinically euvolemic at the time of enrollment. Lastly, the
follow-up duration was relatively short. However, since this
prospective cohort study is still ongoing, the long-term associ-
ation between the biomarkers and clinical outcomes can be
elucidated in the near future. Despite these limitations, to our
knowledge, the present study is the first one to investigate and to
compare the association of baseline NT-proBNP, cTnT, and
hsCRP concentrations with CV and all-cause mortalities in a
large, ethnically homogeneous, incident CAPD patient cohort.
Moreover, based on the data of the present study demonstrating
that among the 3 biomarkers the concentrations of NT-proBNP
and hsCRP in incident CAPD patients even at baseline are the
most significant predictor of CV and all-cause mortality,
respectively, we surmise that the present study may provide
some useful information to the physicians; They may have to
closely monitor incident CAPD patients, especially whose
baseline levels of these biomarkers are high.
In conclusion, among the 3 biomarkers, NT-proBNP and
hsCRP were the best prognostic factors for CV and all-cause
mortalities, respectively, in the Korean incident CAPD patients.
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